In vitro metabolism of human and salmon calcitonins in rat liver and kidney evaluated by liquid chromatography-tandem mass spectrometry

被引:4
作者
Kobayashi, N [1 ]
Yamamura, N [1 ]
Kamagata, M [1 ]
Kurihara, A [1 ]
Ikeda, T [1 ]
机构
[1] Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 140, Japan
关键词
D O I
10.1080/00498250050077977
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Using LC-MS and LC-MS/MS, an in vitro study was conducted on the metabolism of human calcitonin (hCT) and salmon calcitonin (sCT) in rat liver and kidney to determine the rates of metabolism and the positions of hydrolytic cleavage in both peptides. 2. In lysosomal fractions of rat liver and kidney, hCT was degraded 9-12 times faster than sCT. Many metabolites of hCT were produced in the lysosomal fractions, whereas the metabolites of sCT were scarcely found. 3. In the case of the cytosolic fractions, three positions of initial endoproteolytic cleavage were found in hCT, leading to the production of many peptide fragments via subsequent exoproteolytic metabolism. The initial cleavage position of sCT could not be identified precisely, but it was postulated that the rate-determining step in the metabolism of sCT is the endoproteolytic hydrolysis. 4. The studies using pure proteases and protease inhibitors indicated that the metabolism of calcitonins proceeds by initial endoproteolytic cleavage and subsequent exoproteolytic digestion, catalysed by an aspartate-protease in lysosomes and by a metalloprotease and cysteine-protease in combination in the cytosol. 5. The result suggested that the higher in vivo pharmacological activity of sCT compared with that of hCT may be due to a slower metabolism of the former.
引用
收藏
页码:655 / 664
页数:10
相关论文
共 19 条
[1]  
ARVINTE T, 1993, J BIOL CHEM, V268, P6415
[2]   CALCITONIN - PHYSIOLOGY AND PATHO-PHYSIOLOGY [J].
AUSTIN, LA ;
HEATH, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (05) :269-278
[3]   Iodine-123 salmon calcitonin, an imaging agent for calcitonin receptors: synthesis, biodistribution, metabolism and dosimetry in humans [J].
Blower, PJ ;
Puncher, MRB ;
Kettle, AG ;
George, S ;
Dorsch, S ;
Leak, A ;
Naylor, LH ;
O'Doherty, MJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (02) :101-108
[4]   Alteration in pancreatic immunoreactivity of insulin-like growth factor (IGF)-binding protein (IGFBP)-6 and in intracellular degradation of IGFBP-3 in fibroblasts of IGF-II receptor/IGF-II-deficient mice [J].
Braulke, T ;
Dittmer, F ;
Götz, W ;
von Figura, K .
HORMONE AND METABOLIC RESEARCH, 1999, 31 (2-3) :235-241
[5]   ENHANCED POTENCY OF HUMAN CALCITONIN WHEN FIBRILLATION IS AVOIDED [J].
CUDD, A ;
ARVINTE, T ;
DAS, REG ;
CHINNI, C ;
MACINTYRE, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (06) :717-719
[6]   PROCESSING OF CALCITONIN AND EPIDERMAL GROWTH-FACTOR AFTER BINDING TO RECEPTORS IN HUMAN-BREAST CANCER-CELLS (T-47D) [J].
FINDLAY, DM ;
NG, KW ;
NIALL, M ;
MARTIN, TJ .
BIOCHEMICAL JOURNAL, 1982, 206 (02) :343-350
[7]   PROTEIN KINASE-C-INDUCED DOWN-REGULATION OF CALCITONIN RECEPTORS AND CALCITONIN-ACTIVATED ADENYLATE-CYCLASE IN T47D AND BEN CELLS [J].
FINDLAY, DM ;
MICHELANGELI, VP ;
ROBINSON, PJ .
ENDOCRINOLOGY, 1989, 125 (05) :2656-2663
[8]   RELATIONSHIPS BETWEEN HYPOCALCEMIC AND ANORECTIC EFFECT OF CALCITONIN IN THE RAT [J].
GAGGI, R ;
BELTRANDI, E ;
DALLOLIO, R ;
FERRI, S .
PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1985, 17 (03) :209-215
[9]  
GALANTE L, 1971, CLIN SCI, V40, P9
[10]  
GENNARI C, 1994, BRIT J CLIN PRACT, V48, P196